No Love: Chinese Oncology Firms Scramble To Cope With New US Reality

After a high-profile FDA advisory committee rejection of potentially the first "Made In China" cancer drug in the US, from Innovent Bio and partner Lilly, many Chinese oncology companies are now quietly looking for the next step forward.

No Love for Made in China PD-1s from US FDA
CHINESE CANCER DEVELOPERS SCRAMBLE TO COPE AFTER FDA COMMITTEE REQUIRES ADDITIONAL DATA • Source: Alamy

While some front-runners say the result was not surprising, many companies have already started quietly preparing for the next steps and one thing seems to be crystal clear: the US regulator certainly looks to be different this time around.

The Oncology Drug Advisory Committee (ODAC), serving as the outside expert council to the US Food and Drug Administration, voted...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers